Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI
University of Pennsylvania · NCT04251130
This study is trying to see how well a special brain scan can show changes in specific areas of the brain related to memory in people with conditions like Alzheimer's disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | University of Pennsylvania (other) |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT04251130 on ClinicalTrials.gov |
What this trial studies
Processing failed - manual review needed
Who should consider this trial
Good fit: Unknown
Not a fit: Unknown
Why it matters
Potential benefit: Unknown
How similar studies have performed: Unknown
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males and females ≥ 60 years of age. * Part of the NACC longitudinal cohort (IRB# 068200) of the PMC/ADCC with consensus conference designation of cognitively normal or Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) Possible or Probable. * NACC longitudinal visit completed or scheduled within 6 months before or after enrollment in this study. * Women must be post-menopausal or surgically sterile. * An amyloid PET scan, completed as a part of the NACC protocol (IRB# 825943), must be performed or scheduled within 12 months before or after the \[18F\]PI-2620 PET scan. * A brain MRI, completed as a part of NACC protocol (IRB# 068200), must be performed or scheduled within 6 months before or after the \[18F\]PI-2620 PET scan. Scan should be of adequate research quality, including 3 Tesla and/or 7 Tesla high-resolution imaging of MTL structure. Exclusion Criteria: * Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study. * Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan. * Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician. * Have a history of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported. The inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (EPIC or the ADC database)
Where this trial is running
Philadelphia, Pennsylvania
- University of Pennsylvania, School of Medicine — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: David Wolk, MD — University of Pennsylvania
- Study coordinator: Martha Combs
- Email: Martha.Combs@pennmedicine.upenn.edu
- Phone: 215-615-3084
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mild Cognitive Impairment
Last reviewed 2026-05-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.